Healthcare - Press Releases

Basal Cell Carcinoma CSR Highlights

POTSDAM, Germany, April 2, 2025 /PRNewswire/ -- Data4Life, the nonprofit digital health organization, today announced the open-source release of its research platform Data2Evidence (D2E). With this move, Data4Life is equipping researchers and developers worldwide with powerful tools to integrate, manage, and analyze heterogeneous health data. By adopting an open-source strategy, the organization aims to foster scientific collaboration, accelerate innovation, and strengthen the interoperability of health data.

Acquisition enables Landmark Bio to scale capabilities to accelerate development and manufacturing of advanced therapies

BEIJING, April 2, 2025 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young"or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced that the Company had been informed by Mr. Xing Jin, the Company's chairman of the board of directors, chief executive officer, and controlling shareholder, that onMarch 31, 2025, Beauty & Health Holdings Limited, a company incorporated in the British Virgin Islands and controlled by Mr. Xing Jin, purchased a total of 4,544,820 American depositary shares ("ADSs") representing 3,496,015.38 Class A ordinary shares of the Companyin the open marketin accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended, using personal funds (the "Share Purchase"). This increases Mr. Xing Jin's total beneficial ownership to 24.9 % of the Company's outstanding shares[1]. The ADSs were purchased at a price of US$ 0.9 per ADS, for a total aggregate purchase price of US$ 4,090,338.

- Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -

American Lung Association Celebrates 10 Years of LUNG FORCE Advocacy Day on April 9

BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. Edgewise anticipates gross proceeds from the offering to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering is expected to occur on April 3, 2025, subject to the satisfaction of customary closing conditions.

FORT LAUDERDALE, Fla., April 2, 2025 /PRNewswire/ -- Discover how VARP, Inc. is transforming lives by bridging the gap between traditional and modern addiction treatment, highlighting the power of Medication-Assisted Treatment (MAT) and hope.

REYKJAVIK, Iceland, April 2, 2025 /PRNewswire/ -- Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the publication of research in JAMA Neurology, which informs a possible therapeutic strategy to treat a rare form of familial dementia.

REYKJAVIK, Iceland, April 2, 2025 /PRNewswire/ -- Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the publication of research in JAMA Neurology, which informs a possible therapeutic strategy to treat a rare form of familial dementia.

LONDON, April 2, 2025 /PRNewswire/ -- Biopharm, a leading pharmaceutical company in Algeria, has been awarded the prestigious title of 'Excellence in Generic Medicine Development, Algeria, 2024' by Global Brands Magazine (GBM) at the renowned Global Brand Awards. This distinguished recognition underscores Biopharm's exceptional dedication to pioneering innovation and advancing public health through high-quality generic medicines.

STUTTGART, Germany, April 2, 2025 /PRNewswire/ -- Exyte's Executive Board has appointed Katrien Verlinden to the position of President of the Global Business Unit (GBU) Advanced Technology Facilities (ATF) effective April 14, 2025. Based in Singapore, she will report to Mark Garvey who has served as President ATF since January 2020 and since December 2023 also filled the roles of CEO ATF and Executive Board Member. With Verlinden's joining, Mark Garvey will focus on his role as Board Member and CEO of ATF in the future. ATF is Exyte's largest business segment by sales, primarily active in the semiconductor and battery cell sectors.

STUTTGART, Germany, April 2, 2025 /PRNewswire/ -- Exyte's Executive Board has appointed Katrien Verlinden to the position of President of the Global Business Unit (GBU) Advanced Technology Facilities (ATF) effective April 14, 2025. Based in Singapore, she will report to Mark Garvey who has served as President ATF since January 2020 and since December 2023 also filled the roles of CEO ATF and Executive Board Member. With Verlinden's joining, Mark Garvey will focus on his role as Board Member and CEO of ATF in the future. ATF is Exyte's largest business segment by sales, primarily active in the semiconductor and battery cell sectors.

MONTRAL, April 2, 2025 /PRNewswire/ -vopemed (Vope Medical), a pioneering MedTech startup enhancing surgical vision with AI-powered image clarification, has secured an oversubscribed $2.29 million pre-seed funding round to accelerate the development and clinical validation of its technology. This funding marks a significant milestone in vopemed's vision of empowering surgical teams with next-generation tools for safer, more efficient surgeries.

MOBILE, Ala., March 25, 2025 /PRNewswire/ -- Resiliency refers to the ability to adapt and recover from challenges. It involves emotional strength and flexibility that enables individuals to handle life's difficulties. For children, a key component to building that resiliency is having healthy relationships with the adults around them. Parents and caregivers can play a crucial role in fostering this by building trust, setting boundaries, and maintaining open communication.

NASDAQ | TSX: ACB

BOSTON, March 25, 2025 /PRNewswire/ -- Sanctuary Medicinals is proud to announce its victory at the 6th Annual NECANN Cup Boston, securing 4th place in the highly competitive Solvent Concentrates category! This prestigious recognition highlights our commitment to excellence, innovation, and quality in the cannabis industry. Competing against over 100 top cannabis brands across multiple categories, Sanctuary stood out with our Volcanna Unicorn Meat Crumble, impressing a panel of expert judges.

PORT ORANGE, Fla., March 25, 2025 /PRNewswire/ -- Dr. Marco N.Barusco, a pioneer in hair restoration surgery and renowned educator, has been appointed Vice President of the American Academy of Cosmetic Surgery (AACS). This prestigious role reflects his decades-long commitment to advancing cosmetic surgery standards, particularly within hair restoration.

DALLAS, March 25, 2025 /PRNewswire/ -- Loopback Analytics, a leading provider of data-driven market access solutions for health system specialty pharmacies, today announced a strategic partnership with Ballad Health, a 20-hospital health system based in Tennessee. This collaboration aims to accelerate the growth of Ballad Health's specialty pharmacy, ensuring more patients with chronic and complex conditions receive high-touch, coordinated care.

CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ --Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creatingpreciselytargeted therapies for clinically proven kinase targets in cancer, today announced upcoming poster presentations further characterizing the preclinical profiles of its novel ALK-selective inhibitor, neladalkib, and novel ROS1-selective inhibitor, zidesamtinib, at the American Association for Cancer Research (AACR) Annual Meeting 2025 from April 25-30, 2025, in Chicago.

Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models

ROCKLATAN/ROCLANDA holds significant market potential for treating open-angle glaucoma (OAG) and ocular hypertension by effectively reducing IOP. This fixed-dose combination merges the benefits of a Rho kinase inhibitor and a prostaglandin F2 analog, providing superior efficacy compared to monotherapies.

BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and accompanying warrant, for gross proceeds of approximately $10 million, before deducting placement agent fees and offering expenses payable by the Company.

LUND, Schweden, 25. Mrz 2025 /PRNewswire/ -- TFS HealthScience (TFS), ein weltweit fhrendes Auftragsforschungsinstitut (CRO), freut sich, die Ernennung von Miriam Martin, einem langjhrigen Mitglied des Unternehmens, zur Vice President of Business Development, Clinical Development Services (CDS), bekannt geben zu drfen. Mit dieser neuen Funktion wird Miriam auerdem Mitglied des TFS Executive Committee und verstrkt damit das Engagement des Unternehmens fr strategisches Wachstum, Betriebsexzellenz und die Frderung starker Partnerschaften.

CHENGDU, China, March 25, 2025 /PRNewswire/ -- SichuanKelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the investigational new drug application for a radionuclide-drug conjugate (RDC) drug SKB107 (formerly TBM-001) from the Center for Drug Evaluation of the National Medical Products Administration. SKB107 is the first company RDC drug clinical project.